Articles

Final results from the randomized phase 2 trial of trastuzumab deruxtecan in patients with HER2-mutant NSCLC were reported at ASCO 2024 and summarized in this video by Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP. She recaps the efficacy and safety data while highlighting the importance of nurses in assessing and managing adverse events associated with these medications. Read More ›

The Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path is a resource that oncology nurses and navigators can use to assist patients and caregivers in the fight against early-stage breast cancer. Oncology nurses and navigators guide patients through their treatment journey from time of diagnosis into survivorship, providing education, resources, and support. Read More ›

According to the National Cancer Institute, prostate cancer is the most common cancer in US men and the second highest cause of cancer death in this patient population. In fact, an estimated 299,010 new cases will be diagnosed in 2024 and approximately 12.9% of men will receive this diagnosis in their lifetime. Thus, a significant portion of your patients and their loved ones will be affected by this prevalent disease. Test your knowledge now. Read More ›

Experts provide notable points on ovarian function suppression therapy, including suitable patient populations, effective utilization, and valuable navigation approaches. Read More ›